A RANDOMIZED, SINGLE-BLIND, SINGLE-DOSE, THREE-ARM, PARALLEL GROUP STUDY IN HEALTHY SUBJECTS TO DEMONSTRATE PHARMACOKINETIC EQUIVALENCE OF ABP 501 AND ADALIMUMAB: RESULTS OF COMPARISON WITH ADALIMUMAB (EU)

Authors
Category Primary study
JournalANNALS OF THE RHEUMATIC DISEASES
Year 2014
This article has no abstract
Epistemonikos ID: 4e3aa4234c0c5f9e4a85a84bbbe5642d1a176a29
First added on: Feb 06, 2025